UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
August 2024
Commission File Number: 001-41386
OKYO Pharma LTD
(Exact Name of Registrant as Specified in Its Charter)
9th Floor
107 Cheapside
London
EC2V 6DN
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On August 15, 2024, OKYO Pharma LTD (the “Company”) issued this 6K announcing, the company will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, which is being held on Thursday, August 15th.
The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
OKYO Pharma LTD | ||
Date: August 15, 2024 | By: | /s/ Keeren Shah |
Name: | Keeren Shah | |
Title: | Chief Financial Officer |
3 |
EXHIBIT INDEX
Exhibit No. | Description | |
99.1 | News Announcement, dated August 15, 2024 |
4 |
Exhibit 99.1
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
London and New York, NY, August 15, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the company will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, which is being held on Thursday, August 15th.
Management’s pre-recorded company presentation can be accessed on-demand beginning at 7:00 am EDT on the day of the conference.
For additional information, or to register for the conference, please click here. To arrange a virtual 1x1 meeting with OKYO Pharma’s management, please contact your H.C. Wainwright representative.
About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled trial of OK-101 to treat DED.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
-1- |
Enquiries:
OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 | ||
Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
-2- |
!
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M.X1?;)SC\ %J(+FC.;V_S8I.THQ_K8]0IDD231E)%#*>QIQ( )) ZDUR6H?
M$/2+;45TZPCN=5NR<&.R3>!^/0_A6,82G\*-7)1W9UU%16\S3V\N
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M*YN(;.VEN;B18X8D+N[' 50,DUX'86\_QB^)$UY&^(_A%XKO["2ZN_$IU6>VC9H890Y9NY523P3
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M"V1CEEAC" GU.*LT44 5%TO3TOC>K8VPNR